Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 Data suggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback